Clinical trials: Anti-VEGF Treatment, open to volunteers
Radiation Necrosis, High Grade Glioma (III or IV)
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
Cerebral radiation necrosis (CRN) is a severe complication of high-dose radiation for brain metastases (BM) or glioma, which can potentially cause significant neurologic symptoms leading to serious morbidity and impaired quality…
- Conditions
- Radiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases, Radiation Toxicity
- Trial name
- BRAINS (NCT06888817)
- Testing
- Bevacizumab, Dexamethasone
- Where
- 6 sites in Netherlands
- Volunteers
- 408 people
- Sponsor
- The Netherlands Cancer Institute
Locally Advanced / Metastatic Solid Tumors
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with…
- Trial name
- ASCEND (NCT07335497)
- Testing
- CR-001, Paclitaxel, trifluridine and tipiracil
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 540 people
- Sponsor
- Crescent Biopharma, Inc.
Metastatic Colorectal Cancer
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
The goal of this clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.
- Trial name
- NCT06959550
- Testing
- Ivonescimab
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Vestibular Schwannoma
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
This multi-center, observational, post-intervention LTFU study will monitor for safety and efficacy of AAVAnc80- antiVEGF in individuals with vestibular schwannoma who have previously received an intracochlear administration of…
- Trial name
- NCT07503613
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary…
- Trial name
- NCT07368023
- Testing
- Locoregional Therapy (LRT) + Systemic Drug Therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Severe Diabetic Macular Oedema
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
The macula is the centre of the retina; it gives central sight, colour and fine detail. People with diabetes may develop diabetic macular oedema (DMO).
- Trial name
- DAME (NCT06985706)
- Testing
- Subthreshold Micropulse Laser (SML), Anti-VEGF Monotherapy (standard care)
- Where
- 22 sites in United Kingdom
- Volunteers
- 264 people
- Sponsor
- Belfast Health and Social Care Trust
Cancer, Solid Tumor
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Solid tumors pose significant challenges in current therapeutic approaches. Targeted therapy has emerged as a promising avenue, aiming to enhance treatment efficacy while minimizing adverse effects.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Breast Cancer
- Trial name
- PTST_PALBEVA (NCT06307249)
- Testing
- SNP, Palbociclib 125mg, Bevacizumab
- Where
- 2 sites in Lebanon
- Volunteers
- 50 people
- Sponsor
- Lebanese University
Myopic Choroidal Neovascularisation, Anti-VEGF Treatment
The Treatment Burden of Myopic Choroidal Neovascularization
Pathologic myopia (PM) is characterized by progressive eye elongation associated with degenerative changes in the retinal and choroidal tissue.
- Conditions
- Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden
- Trial name
- mCNV burden (NCT07009574)
- Testing
- anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Policlinico Gaspare Rodolico - San Marco Catania
Hepatocellular Carcinoma, Liver Transplantation
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined treatment strategy for patients with hepatocellular carcinoma (HCC) who are beyond the UCSF criteria but intended for…
- Trial name
- NCT07310836
- Testing
- Locoregional Therapy (LRT) + Systemic Drug Therapy
- Volunteers
- 300 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Neovascular Glaucoma, Type 2 Diabetes
Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma
The goal of this observational study is to quantify iris blood flow via non-invasive eye scanning for evaluating ocular lesions in adults aged 18 years and older, including healthy volunteers, patients with type 2 diabetes…
- Trial name
- NCT07722910
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Qilu Hospital of Shandong University
Vestibular Schwannoma
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product…
- Trial name
- NCT06517888
- Testing
- AAVAnc80-antiVEGF via Akouos Delivery Device
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Eli Lilly and Company
Diabetic Macular Edema
Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT
Diabetic macular edema (DME) is a common cause of central visual loss in diabetic patients and a global public health burden around the world.
- Trial name
- DME HOME (NCT06610747)
- Testing
- Home-based Care Monitoring, Aflibercept 2Mg/0.05Ml Inj,Oph, Laser Treatment
- Where
- 4 sites in China
- Volunteers
- 308 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
HCC - Hepatocellular Carcinoma
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
This trial is designed to explore the efficacy and safety of interventional therapy combined with immune checkpoint inhibitors(ICIs) and anti-vascular endothelial growth factor(VEGF) antibody/tyrosine kinase inhibitors in the…
- Trial name
- NCT07157969
- Testing
- Lenvatinib, Pembrolizumab, Atezolizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma Non-resectable
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine…
- Trial name
- CCGLC-001 (NCT05713994)
- Testing
- HAIC, Bevacizumab plus Atezolizumab, Bevacizumab Biosimilar IBI305 plus sintilimab
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Ze-yang Ding, MD
Renal Cell Carcinoma
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).
- Trial name
- NCT07049926
- Testing
- Belzutifan, Zanzalintinib
- Where
- 33 sites in United States, Chile and 6 more
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Corneal Neovascularisation
Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization
The goal of this clinical trial is to evaluate the efficacy and safety of combined fine-needle diathermy and subconjunctival Bevacizumab injection in patients with corneal neovascularization.
- Trial name
- FND-CNV (NCT07642960)
- Testing
- Fine-needle diathermy, Bevacizumab
- Where
- Vietnam
- Volunteers
- 51 people
- Sponsor
- HoChiMinh City Eye Hospital
Retinopathy of Prematurity (ROP), Prematurity Complications
Retinopathy of Prematurity - Visual Function and Retinal Structure
Children born prematurely may develop a characteristic retinal disease named retinopathy of prematurity (ROP). This disease could lead to retinal detachment and blindness.
- Conditions
- Retinopathy of Prematurity (ROP), Prematurity Complications, Cerebral Visual Impairment, Visual Field Defect
- Trial name
- NCT07427719
- Where
- Norway
- Volunteers
- 140 people
- Sponsor
- Oslo University Hospital
Hepatocellular Carcinoma
Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
This study is being done to analyze the safety, tolerability, and efficacy of treatment using combination of anti-VEGF and anti-PD-1/PDL1 antibodies for patients with advanced hepatocellular carcinoma.
- Trial name
- NCT06537908
- Testing
- Anti-PD-1/PD-L1 antibodies, Anti-VEGF
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Diabetic Macular Edema (DME)
Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema
Diabetic macular edema is a frequent complication of long-standing diabetes mellitus in which fluid leaks into the central part of the retina (macula), leading to reduced vision.
- Trial name
- NCT07338097
- Testing
- Aflibercept (2.0 mg), Bevacizumab
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- CMH Multan Institute of Medical Sciences